EDIT
NASDAQ HealthcareEditas Medicine, Inc. - Common Stock
Biotechnology
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
๐ Market Data
| Price | $2.70 |
|---|---|
| Volume | 17,028,444 |
| Market Cap | 414.67M |
| Beta | 2.090 |
| RSI (14-Day) | 30.7 |
| 200-Day MA | $2.63 |
| 50-Day MA | $2.90 |
| 52-Week High | $4.54 |
| 52-Week Low | $1.66 |
| Forward P/E | -3.59 |
| Price / Book | 3.94 |
๐ฏ Investment Strategy Scores
EDIT scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (94/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (6/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find EDIT in your text
Paste any article, transcript, or post โ the tool will extract EDIT and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-09-18.